IQVIA Holdings Inc. (IQV) Enterprise Value (EV): $52.94B
The enterprise value (EV) for IQVIA Holdings Inc. (IQV) is $52.94B as of Wednesday, June 10, 2026.
IQV Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$52.94B
IQV Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.60B | $52.94B |
| Medline Inc. (MDLN) | $30.90B | $44.73B |
| Centene Corporation (CNC) | $31.94B | $21.10B |
| DexCom, Inc. (DXCM) | $29.24B | $26.37B |
| Biogen Inc. (BIIB) | $29.00B | $29.76B |
| Zoetis Inc. (ZTS) | $34.20B | $62.97B |
| Veeva Systems Inc. (VEEV) | $26.73B | $32.05B |
| Agilent Technologies, Inc. (A) | $37.17B | $42.98B |
| Waters Corporation (WAT) | $23.83B | $23.51B |
| Mettler-Toledo International Inc. (MTD) | $22.85B | $31.01B |
Enterprise Value Calculation
Market Cap
$30.60B
Total Debt
$15.95B
Cash
$1.98B
Enterprise Value
$52.94B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
IQVIA Holdings Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for IQVIA Holdings Inc. (IQV)?
- The enterprise value (EV) for IQV stock is $52.94B.
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib